Pcs-499 clinical trials
Also written PCS499 and CTP-499.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses pcs-499 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2011 | 2 |
| 2012 | 1 |
| 2018 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Processa Pharmaceuticals (3) · Concert Pharmaceuticals (3)
Studies
Open first, then newest update. How each study uses pcs-499 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis LipoidicaCompletedPhase 2Processa PharmaceuticalsNCT03698864Written as PCS499
- A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis LipoidicaTerminatedPhase 2Processa PharmaceuticalsNCT04800562Written as PCS499
- A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy PatientsCompletedPhase 2Concert PharmaceuticalsNCT01487109Written as CTP-499
- Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy SubjectsCompletedPhase 1Processa PharmaceuticalsNCT03836222Written as PCS499
- Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney DiseaseCompletedPhase 1Concert PharmaceuticalsNCT01460199Written as CTP-499
- Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499CompletedPhase 1Concert PharmaceuticalsNCT01328821Written as CTP-499